TrialClinical pharmacology and therapeutics2012

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

B Zambrowicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.